Otologic Pharmaceutics, Inc., an Oklahoma City, OK-based development stage pharmaceutical company focused on commercializing technologies that address novel pharmacological solutions for hearing health, closed a financing round of undisclosed amount.
The funding was led by the OCAST Technology Business Finance Program, with participation from INTEGRIS Health and the Oklahoma Medical Foundation (OMRF).
The funding will enable the company to advance its therapeutics for hearing health.
Comnmenting on the round, David Karlman, Otologic Pharmaceutics, Inc., CEO, said: “This capital commitment represents a seminal milestone in advancing our mission to commercialize therapeutics for hearing health.
“The resources are now aligned to continue building our business so that the team of nationally and internationally recognized inner ear medicine experts, world-class biomedical research scientists and proven business leaders can introduce safe and effective solutions for hearing health based on our portfolio of 19 patents we have in-licensed”, he added.
i2E Inc. manages the OCAST Technology Business Finance Program for the State of Oklahoma.